Healthcare / BiotechnologyNasdaqCM
$3.27
-0.28 (-7.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-29.6M · quality 67.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$2M
P/E
N/A
•EV/EBITDA
N/A
•ROE
309.1%
↑Gross Margin
67.2%
↑Debt/Equity
-2.52
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2014–2025 · 11 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-206.1%
FCF / Net income
0.44x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $11.5M · net income $-53.4M · FCF $-23.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | $11.5M | $11.5M | $11.7M | $9.8M | $12.0M | $4.3M | $9.4M | $5.8M | $4.4M | $4.4M | $141523.00 | $258381.00 | $0.00 |
| Net Income | $-53.4M | $-53.4M | $-38.5M | $-41.3M | $-47.5M | $-52600.00 | $-33.8M | $-38.5M | $-32.1M | $-22.0M | $-14.7M | $-16.3M | $-8.6M |
| EBITDA | $-51.7M | $-51.7M | $-36.7M | $-33.1M | $-33.4M | $-39.0M | $-24.9M | $-27.2M | $-29.5M | $-33.7M | $-13.5M | $-12.4M | — |
| EPS | -803.95 | -803.95 | -4574.15 | -29542.20 | -1129857.14 | -4631550.00 | -11812500.00 | — | — | — | — | — | — |
| Gross Margin | 67.2% | 67.2% | 83.3% | 79.1% | 83.1% | — | — | — | — | — | — | — | — |
| Operating Margin | -391.9% | -391.9% | -263.8% | -347.5% | -287.8% | -939.1% | -283.9% | -501.3% | -698.0% | -785.3% | -9599.8% | -4816.7% | — |
| Net Margin | -464.2% | -464.2% | -329.3% | -423.1% | -396.9% | -1.2% | -360.2% | -667.3% | -727.9% | -503.7% | -10410.9% | -6305.2% | — |
| Balance Sheet | |||||||||||||
| Debt/Equity | -2.52 | -2.52 | 5.01 | 7.48 | -53.02 | — | — | — | — | — | -0.74 | 0.93 | — |
| Current Ratio | 0.65 | 0.65 | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||
| Free Cash Flow | $-23.7M | $-23.7M | $-29.6M | $-33.2M | $-34.8M | $-35.0M | $-15.3M | — | $-22.7M | — | $-14.5M | — | — |
| Returns | |||||||||||||
| ROE | 309.1% | 309.1% | -528.4% | -832.5% | 7222.8% | — | -196.5% | -361.1% | -597.2% | -127.3% | 600.4% | -370.3% | 104.5% |
| Valuation | |||||||||||||
| P/B | — | — | 1.16 | 2.07 | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||
| Revenue Growth | -1.5% | -1.5% | 19.8% | -18.4% | — | -53.8% | 62.5% | 30.8% | 1.3% | 2981.6% | -45.2% | — | — |
| EPS Growth | 82.4% | 82.4% | 84.5% | 97.4% | — | 60.8% | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-97.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-4574.15 → -803.95
Residual
-97.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.